VEXAS syndrome: complete molecular remission after hypomethylating therapy.

"Declarations Ethical approvalData were collected under written informed consent (according to the principles of the Helsinki Declaration) as part of the HMA-NGS study, which has been approved by the Institutional Ethics Committee of each participating center. Both patients gave their consent to publish their data. Competing interestsKS served on advisory boards and received lecture fees from BMS/Celgene and Novartis. KSG received honoraria from BMS, Jazz Pharmaceuticals, and Abbvie. MA served on advisory boards for Novartis. MB served on advisory boards and received lecture fees from Jazz Pharmaceuticals and served on advisory boards from FarmaTrust. MB received travel compensation from DKMS. DH received research funding from BMS, Jazz Pharmaceuticals, and lecture fees from BMS/Celgene, Jazz Pharmaceuticals, and Novartis; he served on advisory boards for BMS, Novartis, Jazz Pharmaceuticals, Gilead, Takeda, and Hexal. CT is co-owner and CEO of AgenDix GmbH. CT has received lecture fees and/or participated in advisory boards from Novartis, Jazz Pharmaceuticals, Astellas, Janssen, and Illumina. CT has received research funding from Novartis and Bayer. CG, JAG, EB, and MU declare no potential conflict of interest. Competing interests KS served on advisory boards and received lecture fees from BMS/Celgene and Novartis. KSG received honoraria from BMS, Jazz Pharmaceuticals, and Abbvie. MA served on advisory boards for Novartis. MB served on advisory boards and received lecture fees from Jazz Pharmaceuticals and served on advisory boards from FarmaTrust. MB received travel compensation from DKMS. DH received research funding from BMS, Jazz Pharmaceuticals, and lecture fees from BMS/Celgene, Jazz Pharmaceuticals, and Novartis; he served on advisory boards for BMS, Novartis, Jazz Pharmaceuticals, Gilead, Takeda, and Hexal. CT is co-owner and CEO of AgenDix GmbH. CT has received lecture fees and/or participated in advisory boards from Novartis, Jazz Pharmaceuticals, Astellas, Janssen, and Illumina. CT has received research funding from Novartis and Bayer. CG, JAG, EB, and MU declare no potential conflict of interest."